CXCR4 overexpression is associated with poor outcome in females diagnosed with Stage IV non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 7, 2011, Pages 1169-1178

  Otsuka, Shannon ^a   Klimowicz, Alexander C ^a   Kopciuk, Karen ^a,b   Petrillo, Stephanie K ^a   Konno, Mie ^a   Hao, Desiree ^a   Muzik, Huong ^a   Stolte, Erin ^a   Boland, William ^a   Morris, Don ^a   Magliocco, Anthony M ^a   Bebb, D Gwyn ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

Author keywords

CXCR4; Females; Non small cell lung cancer; Outcome; Stage IV

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; PEROXIDASE;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLUORESCENCE HISTOCHEMISTRY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE HISTOCHEMISTRY; SIGNAL TRANSDUCTION; SMOKING; SQUAMOUS CELL; THORACOCENTESIS; TISSUE MICROARRAY; TRACHEOBRONCHIAL TOILET;

EID: 79959906050     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182199a99     Document Type: Article

References (68)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
2. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291. (Pubitemid 35266288)
3. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290:2149-2158. (Pubitemid 37432975)
4. Sandler AB. Molecular targeted agents in non-small-cell lung cancer. Clin Lung Cancer 2003;5(Suppl 1):S22-S28. (Pubitemid 37265938)
5. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597. (Pubitemid 41007845)
6. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991. (Pubitemid 44343542)
7. Zlotnik A, Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 2000;12:121-127. (Pubitemid 30398626)
8. Schier AF. Chemokine signaling: Rules of attraction. Curr Biol 2003;13: R192-R194. (Pubitemid 36289950)
9. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994;55:97-179.
10. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999;10:463-471. (Pubitemid 29205482)
11. Aiuti A, Webb IJ, Bleul C, et al. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997;185:111-120. (Pubitemid 27039446)
12. Hillyer P, Mordelet E, Flynn G, et al. Chemokines, chemokine receptors and adhesion molecules on different human endothelia: Discriminating the tissue-specific functions that affect leucocyte migration. Clin Exp Immunol 2003;134:431-441. (Pubitemid 37542083)
13. Cho HH, Kyoung KM, Seo MJ, et al. Overexpression of CXCR4 increases migration and proliferation of human adipose tissue stromal cells. Stem Cells Dev 2006;15:853-864. (Pubitemid 46147857)
14. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005;23:879-894. (Pubitemid 41170944)
15. Alsayed Y, Ngo H, Runnels J, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007;109:2708-2717. (Pubitemid 46482062)
16. Fernandis AZ, Prasad A, Band H, et al. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004; 23:157-167. (Pubitemid 38142250)
17. Kang H, Watkins G, Parr C, et al. Stromal cell derived factor-1: Its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 2005;7:R402-R410.
18. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56. (Pubitemid 32225831)
19. Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004;64:8604-8612. (Pubitemid 39552073)
20. Jiang YP, Wu XH, Shi B, et al. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: An independent prognostic factor for tumor progression. Gynecol Oncol 2006;103:226-233. (Pubitemid 44374693)
21. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003;63:3833-3839. (Pubitemid 36793074)
22. Hu J, Deng X, Bian X, et al. The expression of functional chemokine receptor CXCR4 is associated with the metastatic potential of human nasopharyngeal carcinoma. Clin Cancer Res 2005;11:4658-4665. (Pubitemid 41557183)
23. Yoon Y, Liang Z, Zhang X, et al. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 2007;67:7518-7524. (Pubitemid 47206582)
24. Koshiba T, Hosotani R, Miyamoto Y, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: A possible role for tumor progression. Clin Cancer Res 2000;6: 3530-3535.
25. Mori T, Doi R, Koizumi M, et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 2004;3:29-37. (Pubitemid 39193676)
26. Su L, Zhang J, Xu H, et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res 2005;11:8273-8280. (Pubitemid 41746937)
27. Phillips RJ, Burdick MD, Lutz M, et al. The stromal derived factor-1/ CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003;167:1676-1686. (Pubitemid 36760683)
28. Phillips RJ, Mestas J, Gharaee-Kermani M, et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 2005; 280:22473-22481. (Pubitemid 40827903)
29. Spano JP, Andre F, Morat L, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: Pattern of expression and correlation with outcome. Ann Oncol 2004;15:613-617. (Pubitemid 38559598)
30. Minamiya Y, Saito H, Takahashi N, et al. Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2009;68:466-471.
31. Wagner PL, Hyjek E, Vazquez MF, et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: Association with metastasis and survival. J Thorac Cardiovasc Surg 2009;137:615-621.
32. Na IK, Scheibenbogen C, Adam C, et al. Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. Hum Pathol 2008;39:1751-1755.
33. Wald O, Izhar U, Amir G, et al. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J Immunol 2006;177:6983-6990.
34. Fischer T, Nagel F, Jacobs S, et al. Reassessment of CXCR4 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2. PLoS One 2008;3:e4069.
35. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-1327. (Pubitemid 35373567)
36. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Analysis 1999;30:253-270.
37. Wellek S. Testing Statistical Hypotheses of Equivalence. New York, NY: Chapman and Hall/CRC, 2003.
38. Therneau TGP. Modelling Survival Data: Extending the Cox Model. New York, NY: Springer-Verlag, 2000.
39. Somers RH. A new asymmetric measure of association for ordinal variables. Am Soc Rev 1962;27:799-811.
40. Harrell FE. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer-Verlag, 2001.
41. SAS/STAT Software, version 9.2 [program]. Cary, NC: SAS Institute Inc., 2008.
42. A Language and Environment for Statistical Computing [program]. 2.1 version. Vienna: R Foundation for Statistical Computing, 2009.
43. Minami H, Yoshimura M, Miyamoto Y, et al. Lung cancer in women: Sex-associated differences in survival of patients undergoing resection for lung cancer. Chest 2000;118:1603-1609. (Pubitemid 32001783)
44. Ferguson MK, Wang J, Hoffman PC, et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg 2000;69:245-249; discussion 249-250.
45. Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 2006;130:1796-1802. (Pubitemid 46033436)
46. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: Age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002;13: 1087-1093.
47. Visbal AL, Williams BA, Nichols FC III, et al. Gender differences in non-small-cell lung cancer survival: An analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004;78:209 -215; discussion 215. (Pubitemid 38842439)
48. Wakelee HA, Wang W, Schiller JH, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 2006;1:441-446. (Pubitemid 47181421)
49. Hsu LH, Chu NM, Liu CC, et al. Sex-associated differences in non-small cell lung cancer in the new era: Is gender an independent prognostic factor? Lung Cancer 2009;66:262-267.
50. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132. (Pubitemid 41058344)
51. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
52. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500. (Pubitemid 38720929)
53. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
54. Sauve K, Lepage J, Sanchez M, et al. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res 2009; 69:5793-5800.
55. Beattie CW, Hansen NW, Thomas PA. Steroid receptors in human lung cancer. Cancer Res 1985;45:4206-4214. (Pubitemid 16224875)
56. Cagle PT, Mody DR, Schwartz MR. Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res 1990;50:6632-6635. (Pubitemid 20348791)
57. Kaiser U, Hofmann J, Schilli M, et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 1996;67: 357-364. (Pubitemid 26274126)
58. Fasco MJ, Hurteau GJ, Spivack SD. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 2002;188:125-140. (Pubitemid 34242672)
59. Kawai H, Ishii A, Washiya K, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 2005;11:5084-5089. (Pubitemid 41003691)
60. Schwartz AG, Prysak GM, Murphy V, et al. Nuclear estrogen receptor beta in lung cancer: Expression and survival differences by sex. Clin Cancer Res 2005;11:7280-7287. (Pubitemid 41507685)
61. Lee JJ, Maeng CH, Baek SK, et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 2010;70:205-210.
62. Ugocsai K, Mandoky L, Tiszlavicz L, et al. Investigation of HER2 overexpression in non-small cell lung cancer. Anticancer Res 2005;25: 3061-3066. (Pubitemid 41044701)
63. Ganju RK, Brubaker SA, Meyer J, et al. The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 1998;273:23169-23175. (Pubitemid 28417500)
64. Sutton A, Friand V, Brule-Donneger S, et al. Stromal cell-derived factor- 1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res 2007;5:21-33.
65. Pituch-Noworolska A, Majka M, Janowska-Wieczorek A, et al. Circulating CXCR4-positive stem/progenitor cells compete for SDF-1-positive niches in bone marrow, muscle and neural tissues: An alternative hypothesis to stem cell plasticity. Folia Histochem Cytobiol 2003;41: 13-21. (Pubitemid 36215829)
66. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood 2005;106:1901-1910. (Pubitemid 41291700)
67. Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/ CXCR4 axis in bone metastasis. Cancer Metastasis Rev 2006;25:573-587. (Pubitemid 46071864)
68. Geminder H, Sagi-Assif O, Goldberg L, et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor- 1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001;167:4747-4757. (Pubitemid 32954357)